Inhibitors of BCR-ABL tyrosine kinase kill CML cells by stimulating pro-apoptotic BIM and inhibiting anti-apoptotic BCL2, BCLxL and MCL1. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.